--- title: "Heart Failure FINALITY-HF | Sutter Health" description: "A Randomized, Double-blind, Placebo-controlled Pragmatic Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure and Reduced Ejection Fraction Who Are Intolerant of or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists (FINALITY-HF)" url: "https://www.sutterhealth.org/research/clinical-trials/heart-failure-finality-hf-2005599814" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Clinical trials](https://www.sutterhealth.org/research/clinical-trials) / 4. Heart Failure FINALITY-HF # Heart Failure FINALITY-HF **Status:** Open to Enrollment [Email us to enroll](https://www.sutterhealth.org/research/clinical-trials/heart-failure-finality-hf-2005599814#enroll) #### Study details View study details on [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06033950?a=2). #### Locations - Sacramento #### Clinical trial FAQs Information for patients and study volunteers, including [frequently asked questions](https://www.sutterhealth.org/research/faqs). A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists (FINALITY-HF) Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients with heart failure and reduced ejection fraction (HFrEF) who are intolerant or ineligible to receive treatment with steroidal mineralocorticoid receptor antagonists (sMRA). ![Gurpreet S Sodhi, M.D.](https://dyn.mktgcdn.com/p/_DPw7axqv4PbIJjFjLDp5slcyPsexcunwo7V0wWSlII/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100) Gurpreet S Sodhi, M.D. Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/gurpreet-s-sodhi-md-1049681244) ## Sub-Investigators [Zijian Xu, M.D., Ph.D., FACC](https://www.sutterhealth.org/research/investigators/zijian-xu-md-phd-facc-1049681028) , [Michael A Gibson, M.D.](https://www.sutterhealth.org/research/investigators/michael-a-gibson-md-1097247582) ## Email us to enroll - [Email Sacramento](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Heart%20Failure%20FINALITY-HF%20in%20Sacramento&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.) ## Related clinical trials [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) - Clinical trial ### [Heart Failure - TEAM-HF](https://www.sutterhealth.org/research/clinical-trials/advancing-heart-failure-team-hf-1097247574) Trial to Evaluate Safety and Effectiveness of Mechanical Circulatory Support in Patients with Advancing Heart Failure **Status:** Open to Enrollment - Clinical trial ### [Heart Failure COMET-HF](https://www.sutterhealth.org/research/clinical-trials/heart-failure-comet-hf-2015330118) A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial to Assess Efficacy and Safety of Omecamtiv Mecarbil in Patients With Symptomatic Heart Failure With Severely Reduced Ejection Fraction (COMET-HF) **Status:** Open to Enrollment - Clinical trial ### [Heart Failure CONFIRMATION-HF](https://www.sutterhealth.org/research/clinical-trials/heart-failure-confirmation-hf-1095250414) Combined Efficacy and Safety of an Early, Intensive, Management Strategy with Finerenone and SGLT2 Inhibitor in Patients Hospitalized with Heart Failure (CONFIRMATION-HF) **Status:** Open to Enrollment - Clinical trial ### [Heart Failure REDEFINE-HF](https://www.sutterhealth.org/research/clinical-trials/heart-failure-redefine-hf-1095250384) Randomized Trial to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Heart Failure Patients With Left Ventricular Ejection Fraction Greater Than or Equal to 40% Hospitalized Due to an Episode of Acute Decompensated Heart Failure (REDEFINE-HF) **Status:** Open to Enrollment - Clinical trial ### [Heart Failure AIM HIGHer Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System CA\_CP\_340](https://www.sutterhealth.org/research/clinical-trials/heart-failure-aim-higher-cardiac-contractility-modulation-therapy-via-optimizer-smart-mini-system-ca_cp_340-2077445142) Assessment of Implantable CCM in the Heart Failure Group With Higher Ejection Fraction **Status:** Open to Enrollment [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/clinical-trials/heart-failure-finality-hf-2005599814#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Clinical trials","item":"https://www.sutterhealth.org/research/clinical-trials"},{"@type":"ListItem","position":4,"name":"Heart Failure FINALITY-HF"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalWebPage","@id":"https://www.sutterhealth.org/research/clinical-trials/heart-failure-finality-hf-2005599814#medicalwebpage","name":"Heart Failure FINALITY-HF","description":"A Randomized, Double-blind, Placebo-controlled Pragmatic Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure and Reduced Ejection Fraction Who Are Intolerant of or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists (FINALITY-HF)","url":"https://www.sutterhealth.org/research/clinical-trials/heart-failure-finality-hf-2005599814","inLanguage":"en-US","dateModified":"2026-06-01","publisher":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"},"mainEntity":{"@id":"https://www.sutterhealth.org/research/clinical-trials/heart-failure-finality-hf-2005599814#medicaltrial"},"breadcrumb":{"@id":"https://www.sutterhealth.org/research/clinical-trials/heart-failure-finality-hf-2005599814#breadcrumblist"},"mentions":[{"@type":"Person","name":"Gurpreet S Sodhi, M.D.","url":"https://www.sutterhealth.org/research/investigators/gurpreet-s-sodhi-md-1049681244","jobTitle":"Principal Investigator","affiliation":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"}}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalTrial","@id":"https://www.sutterhealth.org/research/clinical-trials/heart-failure-finality-hf-2005599814#medicaltrial","name":"Heart Failure FINALITY-HF","alternateName":"A Randomized, Double-blind, Placebo-controlled Pragmatic Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure and Reduced Ejection Fraction Who Are Intolerant of or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists (FINALITY-HF)","url":"https://www.sutterhealth.org/research/clinical-trials/heart-failure-finality-hf-2005599814","description":"A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists (FINALITY-HF) Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients with heart failure and reduced ejection fraction (HFrEF) who are intolerant or ineligible to receive treatment with steroidal mineralocorticoid receptor antagonists (sMRA).","identifier":"NCT06033950","code":{"@type":"MedicalCode","codeValue":"NCT06033950","codingSystem":"ClinicalTrials.gov"},"sameAs":"https://clinicaltrials.gov/study/NCT06033950?a=2","status":"https://schema.org/Recruiting","healthCondition":[{"@type":"MedicalCondition","name":"Heart Failure"}],"studyLocation":[{"@type":"AdministrativeArea","name":"Sacramento"}]} ```